Nutriband (NTRB) Competitors

Pulmonx (NASDAQ:LUNG) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Do analysts prefer LUNG or NTRB?

Pulmonx presently has a consensus target price of $12.75, indicating a potential upside of 88.61%. Nutriband has a consensus target price of $13.00, indicating a potential upside of 140.74%. Given Nutriband's stronger consensus rating and higher possible upside, analysts plainly believe Nutriband is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Nutriband	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to LUNG or NTRB?

In the previous week, Nutriband had 1 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for Nutriband and 2 mentions for Pulmonx. Nutriband's average media sentiment score of 0.96 beat Pulmonx's score of 0.78 indicating that Nutriband is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nutriband	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals believe in LUNG or NTRB?

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 5.7% of Pulmonx shares are held by company insiders. Comparatively, 54.1% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has better earnings and valuation, LUNG or NTRB?

Nutriband has lower revenue, but higher earnings than Pulmonx. Nutriband is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$83.79M	3.21	-$60.84M	-$1.44	-4.69
Nutriband	$2.02M	29.66	-$5.49M	-$0.71	-7.61

Which has more risk and volatility, LUNG or NTRB?

Pulmonx has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Does the MarketBeat Community prefer LUNG or NTRB?

Pulmonx received 32 more outperform votes than Nutriband when rated by MarketBeat users. Likewise, 45.57% of users gave Pulmonx an outperform vote while only 44.44% of users gave Nutriband an outperform vote.

Company	Underperform	Outperform
Pulmonx	Outperform Votes 36 45.57%	Underperform Votes 43 54.43%
Nutriband	Outperform Votes 4 44.44%	Underperform Votes 5 55.56%

Is LUNG or NTRB more profitable?

Pulmonx has a net margin of -67.31% compared to Nutriband's net margin of -338.51%. Nutriband's return on equity of -54.49% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-67.31%	-55.36%	-33.53%
Nutriband	-338.51%	-54.49%	-48.52%

Summary

Nutriband beats Pulmonx on 10 of the 18 factors compared between the two stocks.